Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 0.79 NOK
Change Today -0.01 / -1.25%
Volume 71.8K
As of 3:22 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

weifa asa (WEIFA) Snapshot

0.80 NOK
Previous Close
0.80 NOK
Day High
0.80 NOK
Day Low
0.77 NOK
52 Week High
04/28/15 - 0.93 NOK
52 Week Low
08/8/14 - 0.50 NOK
Market Cap
Average Volume 10 Days
0.39 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for WEIFA ASA (WEIFA)

Related News

No related news articles were found.

weifa asa (WEIFA) Related Businessweek News

No Related Businessweek News Found

weifa asa (WEIFA) Details

Weifa ASA, through its subsidiary, Weifa AS, operates as an integrated pharmaceutical company. Its products include Paracet and Paracetduo used for pain relief; Proxan for treating menstrual pain; Ibux, an ibuprofen product for menstrual pains, headache, and pains in muscles and joints; Ibux gel, an anti-inflammatory cooling gel for local pain treatment; Paralgin Forte for moderate pain treatment; and Tiger Balsam for sore and stiff muscles, as well as for cold and nasal congestion. The company also offers Nazaren, Nazamér, and Dexyl nasal sprays; and Tussin and Bronkyl medicines for cough. In addition, it provides active pharmaceutical ingredients, including Metformin for use in diabetes II medication, and Opioids for use in pain treatment. Further, the company offers Pyrisept, a non-prescription medicine that is used for cleaning and disinfection of superficial wounds; Aselli, an ointment used for treating superficial sores and wounds; Samin for pains and stiffness in joints caused by degenerative joint disease or arthritis; and dietary supplements under the brand name of bra!. Additionally, it develops drugs comprising CP-4200, a LVT derivative of azacytidine, which acts as a modifier of gene expression; and CP-4033, a ribavirin elaidate, the LVT derivative of ribavirin that is in pre-clinical development for aggressive thyroid cancer. In addition, the company is involved in the research and development of pharmaceuticals and fine chemicals. It operates in Norway, Algeria, Germany, Switzerland, Hong Kong, Great Britain, and internationally. The company was formerly known as Aqualis ASA and changed its name to Weifa ASA in August 2014. Weifa ASA was founded in 1940 and is headquartered in Oslo, Norway.

184 Employees
Last Reported Date: 04/29/15
Founded in 1940

weifa asa (WEIFA) Top Compensated Officers

Chief Executive Officer and Vice President of...
Total Annual Compensation: 482.0K NOK
Chief Operational Officer
Total Annual Compensation: 1.0M NOK
Vice President of Research & Development
Total Annual Compensation: 428.0K NOK
Compensation as of Fiscal Year 2014.

weifa asa (WEIFA) Key Developments

Weifa ASA Announces Executive Changes

Weifa ASA announced the appointment of Simen Nyberg-Hansen as the company's new Chief Financial Officer, effective August 10, 2015. Mr. Nyberg-Hansen replaces Gunnar Manum as CFO who, as previously reported moved to a new position in Vistin Pharma AS. Mr. Nyberg-Hansen has previously served as CFO at both Norman AS and Viking Redningstjeneste International AS. Mr. Hansen joins Weifa from his current position as a consultant and chairman in Dolphitech AS.

Weifa ASA Announces Audited Consolidated and Unaudited Pro Forma Consolidated Earnings Results for the Year 2014

Weifa ASA announced audited consolidated and unaudited pro forma consolidated earnings results for the year 2014. For the year, the company reported total revenue and income of NOK 218,248,000. LBITDA was NOK 31,634,000. LBITA was NOK 33,131,000. LBIT was NOK 37,372,000. The company reported unaudited pro forma consolidated total revenue and income of NOK 314,542,000. EBITDA was NOK 6,660,000. EBITA was NOK 5,540,000. LBIT was NOK 5,584,000. Adjusted total revenue and income was NOK 314,967,000. Adjusted EBITDA was NOK 66,612,000. Adjusted EBITA was NOK 66,173,000. Adjusted EBIT was NOK 55,049,000.

Weifa ASA Reports Earnings Results for the Full Year of 2014

Weifa ASA reported earnings results for the full year of 2014. For the period, the company reported profit has increased from NOK 184.4 million to NOK 189.3 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WEIFA:NO 0.79 NOK -0.01

WEIFA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WEIFA.
View Industry Companies

Industry Analysis


Industry Average

Valuation WEIFA Industry Range
Price/Earnings 3.4x
Price/Sales 2.2x
Price/Book 1.1x
Price/Cash Flow 5.8x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WEIFA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at